Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin to Prevent Progression of Low-risk Localized Prostate Cancer
NCT03769766Phase 3Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2019
- Primary completion
- Nov 2029
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Curcumin with Placebo (2 arms). Primary endpoint: Rate of disease progression at 2 years. Started Mar 2019; status: recruiting.
02
Drugs
curcumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03769766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769766.